ARIAD Pharma (ARIA) – Press Releases
-
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
-
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
-
Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc.
-
Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders
-
ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
-
Takeda to Acquire ARIAD Pharmaceuticals, Inc.
-
ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study
-
ARIAD Announces Data Presentations at American Society of Hematology Meeting
-
ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
-
ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
-
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial
-
ARIAD Announces Data Presentations at the World Conference on Lung Cancer
-
ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month
-
ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology
-
ARIAD Reports Third Quarter 2016 Financial Results
-
ARIAD to Present at the Jefferies 2016 London Healthcare Conference
-
ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Results
-
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib
-
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Ariad Pharmaceuticals Inc. Investors
-
ARIAD Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research
-
ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers
-
ARIAD Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO Meeting
-
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
-
ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia
-
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
-
ARIAD to Present at the Morgan Stanley Global Healthcare Conference
-
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
-
ARIAD Reports Second Quarter and First Half 2016 Financial Results
-
ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results
-
ARIAD Announces Webcast of Its Annual Stockholders Meeting
-
ARIAD Completes Strategic Review and Announces Plans for Growth
-
ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa
-
ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan
-
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
-
ARIAD to Host Analyst & Investor Day in New York City
-
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
-
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary AL
-
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
-
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig®
-
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
-
ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
-
ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
-
ARIAD Announces Pricing and Reimbursement for Iclusig in France
-
ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting
-
ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
-
Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
-
ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results
-
ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research
-
ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
Back to ARIA Stock Lookup
